Zevra Therapeutics Inc Ordinary Shares ZVRA 深 滬
已收盤 08-22 16:00:00 美东时间
9.44
-0.070
-0.74%
華盛通- 最 高9.8291
- 今 開9.55
- 成交量 120.90万股
- 最 低 9.2734
- 昨 收 9.51
- 總市值 5.16亿
- 52周最高 13.16
- 市盈率 靜 --
- 換手率 2.21%
- 52周最低 6.19
- 委 比 29.31%
- 總股本 5467.96万
- 歷史最高 418.40
- 量 比 0.64
- 振 幅 5.84%
- 歷史最低 0.206
- 每 手 1
- 風險率 1.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Zevra Therapeutics gains amid takeover speculation
Zevra Therapeutics (NASDAQ:ZVRA) rose 3% amid takeover speculation. There's talk that Zevra (NASDAQ:ZVRA) may have attracted takeover interest, according to traders, who cited a Betaville "uncooked" ...
08-21 22:55
Zevra治疗公司营收增长26%
罕见病药物开发商Zevra治疗公司（ZVRA）报告营收增长26%并完成1.5亿美元优先审评券（PRV）出售，显著增强了资产负债表实力。该公司正着力扩大市场覆...
08-13 22:36
JMP Securities Maintains Market Outperform on Zevra Therapeutics, Lowers Price Target to $18
JMP Securities analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and lowers the price target from $19 to $18.
08-13 22:27
Zevra Therapeutics Q2 EPS $1.24 Beats $1.13 Estimate, Sales $25.90M Beat $22.49M Estimate
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.13 by 10.22 percent. This is a 358.33 percent increase over losses of $(0.48) per share from
08-13 04:09
Here are the major earnings after the close Tuesday
Major earnings expected after the bell on Tuesday include: CoreWeave (CRWV) Inovio Pharmaceuticals (INO) Luminar Technologies (LAZR) Lumentum Holdings (LITE) Gladstone Investment Corporation (GAIN) Ot...
08-12 22:00
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Zevra Therapeutics announced that its executives will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 13, 2025, at 1:00 p.m. ET. Management will also meet with conference attendees, and a live webcast will be available on Zevra’s Investor Relations website. The company specializes in developing therapies for rare diseases and aims to bring life-changing treatments to patients through data-...
08-06 11:30
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
Zevra Therapeutics, Inc. will report Q2 2025 corporate and financial results on August 12, 2025, via a news release after market close, followed by a conference call/audio webcast at 4:30 p.m. ET. The webcast link and dial-in details are available on Zevra's Investor Relations website. A replay will be accessible for 90 days. Zevra focuses on developing therapies for rare diseases with limited treatment options. For more information, contact Nich...
08-04 11:30
Zevra Therapeutics Has Submitted A Marketing Authorization Application To The European Medicines Agency For The Evaluation Of Arimoclomol For Niemann-Pick Disease Type C
The EMA will review the application under the centralized marketing authorization procedure. If a marketing authorization is granted by the European Commission, the authorization is valid in all EU Member States as well
07-28 18:06
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for arimoclomol to treat Niemann-Pick Disease Type C (NPC), a rare genetic disorder causing lipid buildup in cells. Arimoclomol is the only therapy targeting NPC's underlying cause by improving lipid clearance. The EMA has designated arimoclomol as an Orphan Medicinal Product. Zevra has enrolled 89 patients in Europe through its Expande...
07-28 10:00
